The company focuses on high throughput screening strategies for drug development, with a current emphasis on developing anti-HIV drugs that target Vif and APOBEC3G to address the issue of viral resistance. OyaGen also plans to leverage its expertise in Editing Enzyme technologies to develop therapies for other diseases in the future. Founded in 2003 and based in Rochester, New York, OyaGen is committed to harnessing the power of editing enzymes to revolutionize healthcare.